NCT04000529 - Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions

Non-small Cell Lung CarcinomaHead and Neck Squamous Cell CarcinomaEsophageal SCCGastrointestinal Stromal TumorsColorectal Cancer

Interventions

DRUG

TNO155

Capsule

DRUG

Spartalizumab

Concentrate for solution for infusion

DRUG

Ribociclib

Capsule and tablet

Trial Locations (10)

Novartis Investigative Site, Brussels

Novartis Investigative Site, Westmead

Novartis Investigative Site, Valencia

Novartis Investigative Site, Cologne

Novartis Investigative Site, Singapore

Novartis Investigative Site, Chengdu

Massachusetts General Hospital, Boston

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Barcelona